Top

Published in:

Open Access 01-06-2013 | Review Article

Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review

Authors: Ou Sha, Junfei Niu, Tzi-Bun Ng, Eric Yu-Pang Cho, Xiaoyuan Fu, Wenqi Jiang

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2013

Abstract

Trichosanthin (TCS) as a midterm abortifacient medicine has been used clinically in traditional Chinese medicine for centuries. Additionally, TCS manifests a host of pharmacological properties, for instance, anti-HIV and anti-tumor activities. TCS has been reported to inhibit cell growth of a diversity of cancers, including cervical cancer, choriocarcinoma, and leukemia/lymphoma, etc. This article purported to review the various anti-tumor activities of TCS and the mechanism of apoptosis it induced in these tumor cells. These research progresses provide an insight into cancer research and treatment as well as disclose new pharmacological properties of the ancient but popular Chinese medicine.

Endo Y (1988) Mechanisms of action of ricin and related toxins on the inactivation of ribosomes. In: Frankel AE (ed) Immunotoxins. Kluwier, Boston, pp 75–89CrossRef

Peumans WJ, Hao Q, Damme EJMV (2001) Ribosome-inactivating proteins from plants: more than RAN N-glycosidases? FASEB J 15:1493–1506PubMedCrossRef

Shaw PC, Lee KM, Wong KB (2005) Recent advances in trichosanthin, a ribosome-inactivating protein with multiple pharmacological properties. Toxicon 45:683–689PubMedCrossRef

Stirpe F, Barbieri L (1986) Ribosome-inactivating proteins up to date. FEBS Lett 195:1–8PubMedCrossRef

Sha O, Yew DT, Ng TB, Yuan L, Kwong WH (2010) Different in vitro toxicities of structurally similar type I ribosome-inactivating proteins (RIPs). Toxicol In Vitro 24:1176–1182PubMedCrossRef

Ng TB, Wong JH, Wang H (2010) Recent progress in research on ribosome inactivating proteins. Cur Prot Pept Sci 11:37–53CrossRef

Ng TB, Chan WY, Sze LY, Yeung HW (1991) Trichosanthin induces atresia of ovarian follicles and inhibits steroidogenesis in gonadotropin-primed immature mice. Gen Pharmacol 22:847–849PubMedCrossRef

Zheng YT, Zhang WF, Ben KL, Wang JH (1995) In vitro immunotoxicity and cytotoxicity of trichosanthin against human normal immunocytes and leukemia-lymphoma cells. Immunopharmacol Immunotoxicol 17:69–79PubMedCrossRef

Dallal JA, Irvin JD (1978) Enzymatic inactivation of eukaryotic ribosomes by the pokeweed antiviral protein. FEBS Lett 89:257–259PubMedCrossRef

10.

Wang Y (1990) Trichosanthin (Tin Hua Feng Protein). Science Press, Beijing

11.

Anonymous (1976) Studies on the mechanisms of abortion induction by Trichosanthin. Sci Sin 19: 811–830

12.

Li M, Li X, Li JC (2010) Possible mechanisms of trichosanthin-induced apoptosis of tumor cells. Anat Rec 293:986–992CrossRef

13.

Maraganore JM, Joseph M, Bailey MC (1987) Purification and characterization of trichosanthin. J Biol Chem 262:11628–11633PubMed

14.

Kubota S, Yeung HW, Yang JT (1987) Conformation similarities of ricin A-chain and trichosanthin. Int J Pept Prot Res 30:646–651CrossRef

15.

Collins EJ, Robertus JD, LoPresti M, Stone KL, Williams KR et al (1990) Primary amino acid sequence of a-trichosanthin and molecular models for abrin A-chain and a-trichosanthin. J Biol Chem 265:8665–8669PubMed

16.

Au TK, Collins RA, Lam TL, Ng TB, Fong WP et al (2000) The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase. FEBS Lett 471:169–172PubMedCrossRef

17.

Xia X, Sui S (2000) The membrane insertion of trichosanthin is membrane-surface-pH dependent. Biochem J 349:835–841PubMed

18.

Byers VS, Levin AS, Malvino A, Waites L, Robins RA et al (1994) A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. AIDS Res Hum Retrov 10:413–420CrossRef

19.

Chang HM, Yeung HW, Tso WW, Koo A (1985) Advances in Chinese medicinal materials research. World Scientific, Singapore

20.

Wang Y (1985) Chemistry of trichosanthin, a new biologically active plant protein. In: Chang HM, Yeung HW, Tso WW, Koo A (eds) Advances in Chinese medicinal materials research. World Scientific, Singapore

21.

Liu SL (1991) Primary study on safety of trichosanthin combined with reserpine and testosterone propionate for termination of early and middle stage pregnancy: a clinical report of 7754 cases. Shengzhi Yu Biyun 11:46–50PubMed

22.

Dai RX, Xu GJ, Lin XY, Liu LY, Shen HP et al (1993) Studies on injury-mechanism of trichosanthin on trophoblast cells and choriocarcinoma cells in culture. Shi Yan Sheng Wu Xue Bao 26:411–427PubMed

23.

Chan WY, Huang H, Tam SC (2003) Receptor-mediated endocytosis of trichosanthin in choriocarcinoma cells. Toxicol In Vitro 186:191–203

24.

Wang Y, Mi SL, Lou MY, Gao Y, Chen ZL et al (2005) Enhanced green fluorescence protein tracks trichosanthin in human choriocarcinoma cells as a feasible and stable reporter. Front Biosci 10:2279–2284PubMedCrossRef

25.

Xia XF, Wang F, Sui SF (2001) Effect of phospholipid on trichosanthin adsorption at the air-water interface. Biochim Biophys Acta 1515:1–11PubMedCrossRef

26.

Jiao Y, Liu W (2010) Low-density lipoprotein receptor-related protein 1 is an essential receptor for trichosanthin in 2 choriocarcinoma cell lines. Biochem Biophys Res Commun 391:1579–1584PubMedCrossRef

27.

Zhang CY, Gong YX, Ma H, An CC, Chen DY (2000) Trichosanthin induced calcium-dependent generation of reactive oxygen species in human choriocarcinoma cells. Analyst 125:1539–1542PubMedCrossRef

28.

Zhang C, Gong Y, Ma H, An C, Chen D et al (2001) Reactive oxygen species involved in trichosanthin-induced apoptosis of human choriocarcinoma cells. Biochem J 355:653–661PubMed

29.

Xia X, Hou F, Li J, Ke Y, Nie H (2006) Two novel proteins bind specifically to trichosanthin on choriocarcinoma cell membrane. J Biochem 139:725–731PubMedCrossRef

30.

Tsao SW, Ng TB, Yeung HW (1990) Toxicities of trichosanthin and alpha-momorcharin, abortifacient proteins from Chinese medicinal plants, on cultured tumor cell lines. Toxicon 28:1183–1192PubMedCrossRef

31.

Dou CM, Li JC (2004) Effect of extracts of trichosanthes root tubers on HepA-H cells and HeLa cells. World J Gastroenterol 10:2091–2094PubMed

32.

Dou CM, Li JC (2005) The anti-tumor effect of trichosanthin on HepA-H cells and HeLa cells. Chin J Pathophysiol 21:980–984

33.

Wang P, Chen LL, Yan H, Li JC (2009) Trichosanthin suppresses HeLa cell proliferation through inhibition of the PKC/MAPK signaling pathway. Cell Biol Toxicol 25:479–488PubMedCrossRef

34.

Wang P, Xu S, Zhao K, Xiao B, Guo J (2009) Increase in cytosolic calcium maintains plasma membrane integrity through the formation of microtubule ring structure in apoptotic cervical cancer cells induced by trichosanthin. Cell Biol Int 33:1149–1154PubMedCrossRef

35.

Wang P, Xu J, Zhang C (2010) CREB, a possible upstream regulator of Bcl-2 in trichosanthin-induced HeLa cell apoptosis. Mol Biol Rep 37:1891–1896PubMedCrossRef

36.

Jiang Q, Bai T, Shen S, Li L, Ding H, Wang P (2011) Increase of cytosolic calcium induced by trichosanthin suppresses cAMP/PKC levels through the inhibition of adenylyl cyclase activity in HeLa cells. Mol Biol Rep 38

37.

He JF, Li JC (2006) The growth inhibition and apoptosis of HeLa cells induced with TCS. Acta Anat Sin 37:309–314

38.

Li J, Xia X, Ke Y, Nie H, Smith M et al (2007) Trichosanthin induced apoptosis in HL-60 cells via mitochondrial and endoplasmic reticulum stress signaling pathways. Biochim Biophys Acta 1770:1169–1180PubMedCrossRef

39.

Song H, Huang L, Wang Y, Han Y, You C et al (2010) The effect of trichosanthin on the expression and enzyme activity of DNMT1 gene in Caski cervical cancer cell line. Chin Pharmacol Bull 26:1312–1315

40.

Peng P, Huang L, Wang Y, You C, Cao W et al (2011) Effect of recombinant trichosanthin on proliferation of human cervical cancer Caski cells. China J Chin Mater Med 36:2539–2542

41.

Huang LM, Xing XS, Huang YL (2005) The study on correlation between methylation of p16 gene and apoptosis of cervical carcinoma HeLa cell induced by trichosanthin. Zhongguo Zhongliu Linchuang 32:721–724

42.

Wang Y, Huang L (2007) Study on the relevancy of TSLCl gene methylation and HeLa cellapoptosis. China J Mod Med 17:2575–2578

43.

Zhang Y, Huang L, Wu J (2009) Experimental Study on the Inhibitory Effect of Trichosanthis on Tumor in U14 M ice. Shizhen Med Mat Med Res 20:2389–2390

44.

Takemoto DJ (1998) Effect of trichosanthin an anti-leukemia protein on normal mouse spleen cells. Anticancer Res 18:357–361PubMed

45.

Li J, Xia X, Nie H, Smith MA, Zhu X (2007) PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562. Biochim Biophys Acta 1770:63–70PubMedCrossRef

46.

Zhang K, Xu J, Huang X, Wu L, Wen C et al (2007) Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562. Can Chemother Pharmacol 60:581–587CrossRef

47.

Li YM, Chen JL, Yang AW, Luo R (2007) Purification of EGF-TCS recombinant fusion protein and its targeting action on human tumor cells in vitro. Acta Acad Med Mil Tert 29:1316–1319

48.

Yang HW, Li YM, Lo R (2007) Antitumor effect of recombinant immunotoxin EGF-TCS in nude mice bearing human hepatocellular carcinoma. J South Med Univ 27:1535–1539

49.

Fang EF, Ng TB, Shaw PC, Wong RN (2011) Recent progress in medicinal investigations on trichosanthin and other ribosome inactivating proteins from the plant genus Trichosanthes. Curr Med Chem 18:4410–4417PubMedCrossRef

50.

Gao DF, Wang BQ, Cao GM, Zhang XL (2010) Cloning of trichosanthin gene and its induction effects on the apoptosis of colorectal carcinoma LoVo cell. Fudan Univ J Med Sci 37:157–161

51.

Xu Z, Wu Y, Chen L, Zhang S (1997) Study on the anticolon carcinoma SW-1116 effects of TCS in vivo. Zhejiang Zhongliu 3:110–111

52.

Huang YL, Huang LM (2010) Recent advance on the structure -function relationship of trichosanthin and its cell entry. Lishizhen Med Mat Med Res 21:268–269

53.

Xu J, Gao DF, Yan GL, Fan JM (2009) Induced apoptotic action of recombinant trichosanthin in human stomach adenocarcinoma MCG803 cells. Mol Biol Rep 36:1559–1564PubMedCrossRef

54.

Li CT, Lin CH, Kao TY, Wu MF, Yeh CS et al (2010) The mechanisms of action of Tianhua™ on antitumor activity in lung cancer cells. Pharm Biol 48:1302–1309PubMedCrossRef

55.

Cai Y, Xiong S, Zheng Y (2011) Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM. Cell Mol Immunol 84:359–367CrossRef

56.

Ding B, Chen D, Li X, Hu J (2008) Trichosanthin inhibits growth of breast cancer cells in vitro and in vivo. J Pract Oncol 23:310–313

57.

Shi Z, Shan S, Yuan T, Gui Y, Cao C et al (2009) Mechanism of trichosanthin in inducing apoptosis of mouse prostatic cancer RM-1 cells in vitro. J Chin Med Mat 32:239–242

58.

Bi L, Li H, Zhang Y (1998) Effects of Trichosanthin of cell cycle and apoptosis of murine melanoma cells. Zhongxiyi Jiehe Zazhi 18:35–37

59.

Lu Y, Xia X, Sui S (2001) The interaction of trichosanthin with supported phospholipid membranes studied by surface plasmon resonance. Biochim Biophys Acta 1512:308–316PubMedCrossRef

60.

Xia XF, Zhang F, Shaw PC, Sui SF (2003) Trichosanthin induces leakage and membrane fusion of liposome. IUBMB Life 55:681–687PubMedCrossRef

61.

Zhao J, Ben LH, Wu YL, Hu W, Ling K et al (1999) Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors. J Exp Med 190:101–111PubMedCrossRef

62.

Chan WL, Shaw PC, Tam SC, Jacobsen C, Gliemann J et al (2000) Trichosanthin interacts with and enters cells via LDL receptor family members. Biochem Biophys Res Commun 270:453–457PubMedCrossRef

63.

Li YS, Wu LP, Li KH, Liu YP, Xiang R et al (2011) Involvement of nuclear factor κB (NF-κB) in the downregulation of cyclooxygenase-2 (COX-2) by genistein in gastric cancer cells. J Int Med Res 39:2141–2150PubMedCrossRef

64.

Venkateswararao E, Anh HL, Sharma VK, Lee KC, Sharma N, et al (2012) Study on anti-proliferative effect of benzoxathiole derivatives through inactivation of NF-κB in human cancer cells. Bioorg Med Chem Lett 22:4523–4527

65.

Li F, Mei Y, Wang Y, Chen C, Tu J et al (2005) Trichosanthin inhibits antigen-specific T cell expansion through nitric oxide-mediated apoptosis pathway. Cell Immunol 234:23–30PubMedCrossRef

66.

Zha X, Chen S, Yang L, Li B, Chen Y et al (2011) Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia. Hum Immunol 72:798–804PubMedCrossRef

67.

Hartog H, Van Der Graaf WT, Boezen HM, Wesseling J (2012) Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs. Anticancer Res 32:1309–1318PubMed

68.

Stühmer T, Iskandarov K, Gao Z, Bumm T, Grella E et al (2012) Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells. Anticancer Res 32:453–462PubMed

69.

Wang YY, Ou-Yang DY, Zheng YT (2007) Mechanism of Trichosanthin against human leukemia/lymphoma cells in vitro. J Exp Hematol 15:729–732

Title: Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review
Authors: Ou Sha
Junfei Niu
Tzi-Bun Ng
Eric Yu-Pang Cho
Xiaoyuan Fu
Wenqi Jiang
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2096-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan

Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer

A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

A UGT1A128 and 6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer